Home · Healthcare M&A · Sell a Gastroenterology Practice in NJ

Specialty Practice M&A · 2026

Sell a Gastroenterology Practice in NJ

Gastroenterology is one of the most actively consolidated medical specialties in NJ in 2026, driven by PE-backed GI platforms aggressively acquiring practices with ambulatory endoscopy center (AEC) ownership. The endoscopy ASC component is the single largest multiple driver — practices with owned or syndicated AEC stakes trade at 7×–9× EBITDA while non-ASC GI groups typically trade at 5×–7×. Multi-physician groups with high-volume endoscopy operations attract premium auction dynamics.

2026 NJ gastroenterology practice multiples

NJ gastroenterology practices typically sell at 5×–8× EBITDA. The high end is driven by ambulatory endoscopy center (AEC) ownership, endoscopy procedure volume, multi-physician groups, hepatology subspecialty, pathology in-house, and clean commercial-insurance payer mix.

Sub-specialty / CategoryTypical Multiple
General GI with AEC ownership7×–9× EBITDA — premium segment
General GI without AEC5×–7× EBITDA
Hepatology subspecialty5×–8× EBITDA — specialty value-add
Inflammatory bowel disease (IBD) specialty5×–7× EBITDA
Multi-physician groups (3+ MDs)+0.5×–1× multiple uplift vs. solo

Active PE buyers acquiring NJ gastroenterology practices

Premium NJ gastroenterology practice auctions in 2026 typically produce 3–6 competing LOIs from PE-backed platforms. Multi-platform competition is one of the most material drivers of final sale price — reaching the right buyers in the right sequence makes a measurable difference to net proceeds.

Key value drivers

Regulatory considerations for NJ/NY gastroenterology practice sales

GI M&A in NJ runs through standard CPOM compliance. AEC ownership is critical: NJ AECs operate under NJ Department of Health licensure (typically as a Class C or Class D ambulatory care facility). Change-of-ownership reviews for NJ AECs are detailed but typically faster than full ASCs. NY GI practices with AECs require PHHPC CON for 10%+ ownership changes. Stark Law applies to endoscopy referrals to owned AECs — federal in-office ancillary services exception protects properly-structured arrangements; PE platforms have well-tested MSO templates.

Frequently asked questions

What multiple does a NJ gastroenterology practice sell for in 2026?

NJ GI practices with AEC ownership typically sell at 7×–9× EBITDA. GI practices without AEC trade at 5×–7×. The single biggest multiple driver is endoscopy center ownership.

Which PE GI platforms are buying NJ practices?

GI Alliance (Apollo Global Management), United Digestive (FFL Partners), US Digestive Health (Amulet Capital), and PE Gastro Health are the most active in NJ in 2026. Premium NJ GI auctions with AEC ownership produce 4–6 competing LOIs regularly.

How does AEC ownership affect my practice valuation?

Dramatically. AEC ownership stake adds 2×–3× EBITDA above non-AEC counterparts. Endoscopy facility-fee revenue flows into practice EBITDA at high margins. If you don't currently have AEC stake, consider whether timing supports adding before sale — the multiple uplift typically pays back the AEC stake cost within 18 months at close.

How long does a NJ GI practice sale take?

Typical NJ GI practice sales close in 8–12 months. AEC-included transactions add 2–3 months. Multi-physician groups take 10–14 months due to physician comp negotiation.

Does Nexus Bridge charge upfront fees for GI practice sales?

No. Success-only commission. You pay nothing until your practice sells.

How Nexus Bridge handles a gastroenterology practice engagement

  1. Free 30-minute discovery call. Confidential conversation about your practice, target valuation, and sale timing. $0, no obligation.
  2. Free evidence-based valuation. Comparable transaction analysis using real NJ/NY/CT data. Delivered in writing within 7 days.
  3. Engagement letter signing. $0 upfront, success-only commission. 12-month exclusivity, 12-month named-buyer tail.
  4. Listing preparation. Financial normalization, CIM preparation, regulatory pre-screening specific to your specialty and state.
  5. Targeted buyer outreach. PE-platform engagement with the specific gastroenterology practice buyers active in your sub-specialty.
  6. LOI negotiation and selection. Multiple LOIs negotiated in parallel where possible.
  7. Due diligence coordination. QoE, legal, regulatory, operational diligence managed in parallel.
  8. Regulatory transition. CON (NY Article 28), OMH (NY Article 31/MHOTRS), NJ DOH, CMS PECOS, Medicaid eMedNY, commercial payer credentialing managed against close.
  9. Close and post-close transition. Typically 8–14 months from listing to funded close depending on regulatory complexity.

Ready to discuss your gastroenterology practice sale?

Schedule a free confidential 30-minute conversation. We'll review your practice profile, give you a realistic valuation range, and tell you which PE platforms or strategic acquirers fit your specific situation. $0 upfront, no obligation.

Related: Healthcare M&A NJ pillar · Sell an ASC · Sell a Medical Practice · Healthcare M&A Glossary